Results: With a minimum follow-up of 32.4 mo (data cutoff: Sep 13, 2019), median OS in ITT-WT pts was 19.0 mo in Arm A vs 14.7 mo in Arm C (HR, 0.84; 95% CI: 0.71, 1.00; Table). published online before print SITC 2019 . Gr 3-4 treatment-related AEs occurred in 52.1%, 36.5% and 54.5% of pts with liver mets in the ABCP, ACP and BCP arms, respectively. Secondary endpoints included PFS and OS in the ITT and PD-L1 expression subgroups. Thank you for sharing this Cancer Research article.

IMpower150: The IMpower150 trial final analysis showed the quadruplet ABCP to be superior to BCP in both the ITT wild type and Coprimary endpoints were investigator-assessed PFS and OS in ITT wild-type (WT; no EGFR or ALK genetic alterations) pts. 37, no. Doses were: A, 1200 mg; B, 15 mg/kg; C, AUC 6 mg/mL/min; P, 200 mg/m2. EASL International Liver Congress 2020. ASCO 2020. Esmo 2020 preview – late-breaking immunotherapy. Benefit with ABCP vs BCP extended to key subgroups, including pts with baseline (BL) liver mets, which is a poor prognostic factor in metastatic NSCLC. Read our.

ABCP over BCP (95% ci: 0.31 to 1.14). IMpower150 final analysis: Efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups [abstract]. According to research presented as part of the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting (Abstract CT216), the chemoimmunotherapy regimen of atezolizumab, bevacizumab, carboplatin, and paclitaxel resulted in numerical—but statistically insignificant—improvement in overall survival compared with the same regimen without atezolizumab in patients with metastatic nonsquamous non–small cell lung cancer. ASCO Connection Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA Background: The Ph III IMpower150 study ([NCT02366143][1]) showed PFS and OS benefit with atezo + bev + carboplatin (carbo) + paclitaxel (pac; ABCP; Arm B) vs bev + carbo + pac (BCP; Arm C) as 1L treatment (tx) for patients (pts) with metastatic nsq NSCLC. May 26, 2019. ESMO IO 2019. Esmo 2020 preview – a kidney cancer showdown gets star billing .

Coprimary endpoints were OS and investigator-assessed PFS in ITT–wild-type pts. Editorial Roster ASCO Daily News

(May 20, 2019) Exploratory analyses included efficacy and safety in pts with liver mets. ESGO 2019. Reviewers We do not retain these email addresses. Posted May 13, 2020 We are grateful to everyone—including the attendees, speakers, and sponsors—who made the AACR Virtual Annual Meeting I such a success. ESMO Asia 2019. Similar outcomes were not seen …

Copyright © 2020 by the American Association for Cancer Research. AACR 2020. JNCCN: How To Manage Cancer Care During COVID-19 Pandemic, Non-Small Cell Lung Cancer Coverage from Every Angle, By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Big pharma spinouts grow up. ASCO GI 2020.

APASL 2020… Permissions, Authors Asco 2020 – after Tecentriq’s liver win the spotlight falls on Merck and Astra. Both arms A and C experienced improvements in overall survival for subgroups for tumor cells 1/2/3 and tumor-infiltrating immune cells 1/2/3 wild type PD-L1, whereas neither arm experienced an improvement in overall survival in subgroups for tumor cells 0 or tumor-infiltrating immune cells 0 wild type. Journal of Cancer Research ISSN: 0099-7013 9012-9012. In pts with EGFR/ALK+ tumors and pts with baseline liver mets, OS was comparable in Arms A and C; continued OS benefit in these subgroups was seen in Arm B vs C. The safety profile of each regimen was consistent with previously reported data at the second interim OS analysis (data cutoff: Jan 22, 2018).

Conquer Cancer Foundation Clinical benefit was also seen in pts with EGFR-mutant or ALK-positive (EGFR/ALK+) tumors. September 11, 2020. The ASCO Post CancerLinQ Cancer Research Online ISSN: 1538-7445 The historic and groundbreaking two-day virtual meeting attracted more than 61,000 registrants from 140 countries. This analysis aims to further understand the efficacy of atezo + bev + chemo in key subgroups: PD-L1 expression subgroups … This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Posted: Wednesday, May 13, 2020. APASL 2020. SMR 2019. AdventHealth Cancer Institute, Orlando, FL; Rocky Mountain Cancer Centers, Denver, CO; Azienda Unità Sanitaria Locale della Romagna, Ravenna, Italy; Prince of Wales Hospital, Hong Kong, China; Swedish Cancer Institute, Seattle, WA; Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; Instituto Nacional del Torax, Santiago, Chile; Moscow City Oncology Hospital, Moscow, Russian Federation; New England Cancer Specialists, Scarborough, ME; Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France; Genentech, Inc., South San Francisco, CA; LungenClinic, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany, Professional English and Academic Editing Support, https://doi.org/10.1200/JCO.2019.37.15_suppl.9012, Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update, Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline, Prognostic Index for Acute- and Lymphoma-Type Adult T-Cell Leukemia/Lymphoma, Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update, Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update, Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update, Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline, Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial, American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options, Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia, 2318 Mill Road, Suite 800, Alexandria, VA 22314, © 2020 American Society of Clinical Oncology. Disclosure: For full disclosures of the study authors, visit abstractsonline.com.

ESMO Breast Cancer 2020. Similar outcomes were not seen with atezo + chemo (IMpower150 [atezo + CP; ACP]; IMpower130; IMpower132), suggesting that the addition of bev to atezo + chemo is important for conferring clinical benefit in these pts. EASL Liver Cancer Summit 2020. Editor's Picks. Here we further explore characteristics and responses of pts with BL liver mets in IMpower150.

Enter words / phrases / DOI / ISBN / authors / keywords / etc. Clinical trial information: NCT02366143. ISPOR 2019. Meeting Abstracts, About TAPUR Study. ILCA 2020. WCGC 2020. Advertisers, Journal of Clinical Oncology Results: The data capture ≥ 20-mo follow-up in ITT pts (data cutoff: Jan 22, 2018). JCO Global Oncology Institutions Archive April 22, 2020. AACR 2020.

©2020 American Association for Cancer Research.

ESMO Breast Cancer 2020. JCO Clinical Cancer Informatics By: Kayci Reyer Cancer Research Print ISSN: 0008-5472

According to research presented as part of the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting (Abstract CT216), the chemoimmunotherapy regimen of atezolizumab, bevacizumab, carboplatin, and paclitaxel resulted …

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail.

CSCO 2020. The absolute median overall survival in months for all the EGFR+ patients presented at AACR 2020 was BCP 18.1 months, ACP 19.0 months and ABCP 29.4 months.